On August 27, 2025 ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics, reported the conditional marketing authorization of Zemcelpro by the European Commission (EC) for the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available (Press release, ExCellThera, AUG 27, 2025, View Source [SID1234655533]). This EC decision authorizes the marketing of Zemcelpro in all European Union member states, as well as Iceland, Norway and Liechtenstein.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zemcelpro, also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.
In Europe, over 10,000 patients each year are diagnosed with haematological malignancies—including leukemias and myelodysplastic syndromes—that require stem cell transplant. While access to transplant has improved in recent years, a number of patients still cannot access suitable donor cells. Barriers include the absence or unavailability of a compatible donor or the inability to secure donor cells within the therapeutic window for transplant, which can be especially short in urgent cases. Unlike documented transplant procedures which are well-tracked through national registries, no official statistics exist for patients who miss the opportunity for a potentially curative transplant—a group that includes a disproportionately high number of individuals from ethnic minority backgrounds.
"The curative potential of allogeneic stem cell transplantation is still limited by the access to a suitable donor. The access to stem cell donation according to the stringent disease course is one of the major limiting factors for success," said Dr. Fabio Ciceri, Professor of Hematology, Vita-Salute San Raffaele University, Millan, Italy. "UM171 Cell Therapy offers an option timely available for patients in need."
Patients with blood cancers who do not receive the stem cell transplant they require represent a significant burden to healthcare systems, driven by ongoing medical needs, disease progression, complications, hospitalizations and supportive/palliative care. Beyond this, the societal impact is profound, with premature deaths leading to lost productivity and considerable emotional and economic strain on families and communities.
"Each year, thousands of people across Europe are diagnosed with blood cancers that require potentially life-saving allogeneic stem cell transplantation. Yet some are left without access to suitable donor-derived blood stem cells, facing a critical and unmet medical need," said Dr. J. (Jurjen) Versluis, Internist-Hematologist and Principal Investigator, Erasmus MC, Rotterdam, The Netherlands.
Zemcelpro is an innovative, one-time cell therapy with curative intent, developed to give blood cancer patients without access to suitable donor cells the transplant they urgently need. By enabling more patients to receive a life-saving transplant, Zemcelpro has the potential not only to save lives but also to reduce the healthcare and societal burden associated with these devastating conditions.
The timing of Zemcelpro availability in individual countries will depend on several factors, including the completion of national reimbursement procedures. In the meantime, Cordex Biologics is working closely with national health authorities to enable early access for eligible patients ahead of the reimbursement process, and is engaging with leading stem cell transplantation centers to establish a network of treatment centers for the future administration of Zemcelpro.
"This authorization marks a pivotal milestone in delivering on the therapeutic promise of Zemcelpro for adults battling life-threatening haematological malignancies. As the first and only cell therapy approved for patients without access to suitable donor cells, Zemcelpro offers a vital new stem cell transplant option — and renewed hope — for those who have been left without one," said David Millette, CEO of ExCellThera and Cordex Biologics.
Additional regulatory filings are planned for Zemcelpro with other health authorities, including in the US, Canada, the UK, and Switzerland. Cordex Biologics is also actively seeking strategic partnerships to support and accelerate the commercialization of Zemcelpro in Europe and other international markets.
The safety of Zemcelpro is consistent with the well-characterized safety profile of conventional allogeneic blood stem cell transplantation for haematological malignancies following myeloablative conditioning.
For full details on the Warnings and Precautions for Use and Adverse Reactions (including appropriate management), please refer to the EU Summary of Product Characteristics (SmPC) of Zemcelpro.
About Conditional Marketing Authorizations (CMAs)
CMAs are for medicines that fulfil a significant unmet medical need such as being for serious and life-threatening diseases, where no satisfactory treatment methods are available or where the medicine offers a major therapeutic advantage. A CMA is granted where comprehensive clinical data is not yet complete, but the benefit of the medicine to address a significant unmet need outweighs the need for data that will become available in the future. CMAs are valid for one year and renewable annually with ongoing regulatory review of data.
About Zemcelpro
Zemcelpro, also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.
Zemcelpro, developed by Cordex Biologics, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.
Zemcelpro has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.
The use of Zemcelpro in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being investigated.
Zemcelpro is a registered trademark of Cordex Biologics.
The product safety and efficacy have not yet been established by other regulatory agencies, such as the FDA, the MHRA and Health Canada.